Department of Dermatology and Allergy, Hannover Medical School (MHH), Carl-Neuberg-Str.1, 30625, Hannover, Germany.
Cluster of Excellence RESIST (EXC 2155), Hannover Medical School (MHH), Hannover, Germany.
Sci Rep. 2023 Oct 3;13(1):16628. doi: 10.1038/s41598-023-42595-z.
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion whether skin-infiltrating Th17 cells may underlie this phenomenon. This study aimed to investigate the potential of allergen-induced, immune-cell derived IL-17 on the induction of inflammatory processes in keratinocytes. Peripheral blood mononuclear cells derived from respectively sensitized AD patients were stimulated with house dust mite (HDM) extract and cell culture supernatants were applied subsequently in absence or presence of secukinumab to primary human keratinocytes. Hereby we confirm that the immune response of sensitized AD patients to HDM contains aside from type-2 cytokines significant amounts of IL-17. Blocking IL-17 efficiently reduced the stimulation-induced changes in keratinocyte gene expression. IL-17-dependent transcriptional changes included increased expression of the cytokines IL-20 and IL-24 as well as Suppressor of Cytokine Siganling 3 (SOCS3), a negative feedback-regulator of the STAT3/IL-17/IL-24 immune response. We conclude that the immune response to HDM can induce pro-inflammatory cytokines from keratinocytes in AD, which in part is mediated via IL-17. Targeting IL-17 may turn out to be a reasonable alternative therapy in a subgroup of patients with moderate to severe AD and HDM sensitization.
特应性皮炎(AD)患者亚组对针对 2 型炎症关键因子的生物制剂治疗无应答,目前仍在讨论是否真皮浸润的 Th17 细胞是这种现象的基础。本研究旨在研究过敏原诱导的、免疫细胞来源的白细胞介素 17(IL-17)在角质形成细胞炎症过程诱导中的潜在作用。分别从致敏 AD 患者中提取外周血单核细胞,用屋尘螨(HDM)提取物刺激,随后在不存在或存在 secukinumab 的情况下将细胞培养上清液应用于原代人角质形成细胞。在此,我们证实了致敏 AD 患者对 HDM 的免疫反应除了 2 型细胞因子外,还含有大量的 IL-17。阻断 IL-17 可有效减少刺激诱导的角质形成细胞基因表达变化。IL-17 依赖性转录变化包括细胞因子 IL-20 和 IL-24 的表达增加以及细胞因子信号转导抑制因子 3(SOCS3),这是 STAT3/IL-17/IL-24 免疫反应的负反馈调节剂。我们得出结论,AD 患者对 HDM 的免疫反应可以诱导角质形成细胞产生促炎细胞因子,其中部分是通过 IL-17 介导的。靶向 IL-17 可能成为中重度 AD 患者和 HDM 致敏亚组的一种合理替代治疗方法。
Biochim Biophys Acta Mol Basis Dis. 2020-2-7
J Physiol Pharmacol. 2020-4
Iran J Allergy Asthma Immunol. 2016-8
J Allergy Clin Immunol. 2002-3
J Clin Aesthet Dermatol. 2024-11
Dermatol Ther (Heidelb). 2023-1
J Dtsch Dermatol Ges. 2022-1
Dermatitis. 2021
J Eur Acad Dermatol Venereol. 2021-6
Science. 2021-1-22
J Allergy Clin Immunol. 2021-1
J Allergy Clin Immunol. 2021-1